IGF2BP3 prevent HMGB1 mRNA decay in bladder cancer and development

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) is an RNA-binding protein implicated in tumorigenesis.
• IGF2BP3 dysregulation is common in cancers, but its regulatory mechanisms and therapeutic potential in bladder cancer are poorly understood.

Purpose of the Study:

• To elucidate the genetic and epigenetic regulation of IGF2BP3 in bladder cancer.
• To investigate the functional role of IGF2BP3 and its downstream targets in bladder cancer progression.
• To explore the therapeutic potential of targeting the IGF2BP3-HMGB1 axis.

Main Methods:

• Quantitative RT-PCR and Western blotting for gene and protein expression analysis.
• Bisulfite sequencing PCR for promoter methylation analysis.
• Luciferase reporter assays to study miRNA regulation.
• Cell proliferation, migration, invasion assays, and xenograft models to assess functional roles.
• RNA immunoprecipitation and mRNA stability assays to investigate downstream targets.

Main Results:

• IGF2BP3 is significantly upregulated in bladder cancer, correlating with advanced stage, grade, and poor prognosis.
• IGF2BP3 upregulation is driven by copy number gain and promoter hypomethylation; miR-320a-3p acts as a negative regulator.
• IGF2BP3 promotes bladder cancer proliferation, migration, and invasion by enhancing HMGB1 mRNA stability and expression.
• Inhibition of HMGB1 reversed the pro-cancer effects of IGF2BP3 overexpression.

Conclusions:

• Genetic and epigenetic alterations drive IGF2BP3 overexpression in bladder cancer.
• The IGF2BP3-HMGB1 axis is a critical driver of bladder cancer progression.
• Targeting the IGF2BP3-HMGB1 pathway presents a promising therapeutic strategy for bladder cancer.